Threshold Pharma leaps as it names new COO

21 March 2016

US clinical-stage cancer drug develop Threshold Pharmaceuticals (Nasdaq: THLD) saw its share leap 9.2% to $0.55, after the company announced the appointment of Stewart Kroll as chief operating officer.

Mr Kroll will serve as the company’s principal operating officer, will continue to report to chief executive Barry Selick, and will be responsible for the design and execution of Threshold’s clinical development programs.

“Not only does Stew have a tremendous amount of clinical development and operational experience, he is also one of the most driven and effective leaders with whom I have worked,” said Dr Selick, adding: “It’s an honor to appoint Stew to this position and I look forward to all of us at Threshold continuing to benefit from his expertise and example.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK